Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.

Maeda, T; Hiura, A; Uehara, J; Toyoshima, R; Nakagawa, T; Yoshino, K

Maeda, T; Hiura, A; Uehara, J; Toyoshima, R; Nakagawa, T; Yoshino, K.

Afiliação

Maeda T; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Hiura A; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Uehara J; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Toyoshima R; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Nakagawa T; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Yoshino K; Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Br J Dermatol ; 186(3): 587-588, 2022 03.

Article em En | MEDLINE | ID: mdl-34747503

Assuntos

Melanoma; Neoplasias Cutâneas; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Humanos; Ipilimumab/efeitos adversos; Melanoma/patologia; Nivolumabe/efeitos adversos; Neoplasias Cutâneas/patologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Limite: Humans Idioma: En Revista: Br J Dermatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google